Skip to content

Study · Non-randomized trial · n = 14 · 1995

5 results

A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer.

Ron IG, Wigler N, Merimsky O, Inbar MJ, Chaitchik S

Cancer investigation1 Jan 1995Cited by 16 (Europe PMC)

PMID7743379 (opens in a new tab)DOI10.3109/07357909509094461 (opens in a new tab)PepBankPUB-07743379
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In chemotherapy-pretreated ovarian cancer patients, decapeptyl produced no complete or partial responses.

    In plain wordsIn ovarian cancer patients who had failed chemotherapy, decapeptyl produced no complete or partial responses.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeComplete or partial responses
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 1 month to 28 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no complete or partial responses.
    1 context sentence
    Summary · context
    Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist.
  2. 02HumanNon-randomized trialEfficacy outcome

    In pretreated ovarian cancer patients, decapeptyl was associated with disease stabilization in 57%.

    In plain wordsIn pretreated ovarian cancer patients, 57% had stable disease during decapeptyl treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableDisease stabilization
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 1 month to 28 weeksAs given in this study (human).

    Measurements

    Disease stabilization
    57%
    decapeptyl
    Patients with disease stabilization
    8 patients
    decapeptyl

    Source sentences

    Summary
    Eight patients (57%) had disease stabilization with a median progression-free interval of 14 weeks (range 4-28 weeks).
    1 context sentence
    Summary · context
    Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist.
  3. 03HumanNon-randomized trialSafety outcome

    In pretreated ovarian cancer patients, toxicity with decapeptyl was mild, with hot flushes in 2 patients.

    In plain wordsIn pretreated ovarian cancer patients, side effects during decapeptyl treatment were mild, with hot flushes in 2 patients.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHot flushes
    Study

    n = 14

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 1 month to 28 weeksAs given in this study (human).

    Measurements

    Patients with hot flushes
    2 patients
    decapeptyl

    Source sentences

    Summary
    The regimen was well tolerated with only mild toxicity observed (hot flushes in 2 patients).
    1 context sentence
    Summary · context
    Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist.
  4. 04HumanNon-randomized trialEfficacy outcome

    In ovarian cancer patients with stabilization during decapeptyl, the median progression-free interval was 14 weeks.

    In plain wordsIn ovarian cancer patients with stable disease during decapeptyl, the median time without progression was 14 weeks.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableProgression-free interval in stabilized patients
    Study

    n = 8

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 1 month to 28 weeksAs given in this study (human).

    Measurements

    Median progression-free interval
    14 weeks
    stabilized patients
    Progression-free interval range
    4 to 28 weeks
    stabilized patients

    Source sentences

    Summary
    Eight patients (57%) had disease stabilization with a median progression-free interval of 14 weeks (range 4-28 weeks).
    1 context sentence
    Summary · context
    Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist.
  5. 05HumanNon-randomized trialEfficacy outcome

    All other ovarian cancer patients developed progressive cancer after the first LHRH agonist injection.

    In plain wordsAll other ovarian cancer patients had cancer progression after the first injection.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableProgressive cancer
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 1 month to 28 weeksAs given in this study (human).

    Source sentences

    Summary
    All other patients developed a clear progressive cancer after the first injection of LHRH agonist.
    1 context sentence
    Summary · context
    Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.